Tailoring treatment for triple-negative breast cancer

Triple-negative breast cancer is a particularly aggressive form of the disease with no specific treatment. In a new study led by the University of Pennsylvania’s Rumela Chakrabarti, researchers discovered that, in contrast to many other cancer types, activation of the interferon gamma signaling contributes to disease progression and spread. The findings may help doctors choose a personalized treatment strategy for triple-negative breast cancer patients, depending on their cancer subtype.